Last reviewed · How we verify
Tested Irbesartan Tablet
At a glance
| Generic name | Tested Irbesartan Tablet |
|---|---|
| Sponsor | The Affiliated Hospital of Qingdao University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bioequivalence Study of Two Irbesartan in Healthy Chinese Subjects (PHASE1)
- A Bioequivalence Trial of Irbesartan Tablets（0.15g） in Healthy Chinese Subjects (PHASE1)
- Multiple Treatments for Ebola Virus Disease (EVD) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tested Irbesartan Tablet CI brief — competitive landscape report
- Tested Irbesartan Tablet updates RSS · CI watch RSS
- The Affiliated Hospital of Qingdao University portfolio CI